Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis.

Onco Targets Ther · 2016 · PMC4907737 · PMID 27354814

Europe PMC DOI

hedged sentence

0.0440

closest p · 0.9× alpha

0.0440

boldest claim

The sentences

slightly significantP =0.044actually significant

Meta-analysis showed that the difference in the values of RR was slightly significant in the disease control rate (RR =1.09, 95% CI: 1.00–1.19, P =0.044) ( Figure 4 ).

also in 1,762 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.